12:00 AM
 | 
Apr 14, 2014
 |  BioCentury  |  Finance

Double vision

NuCana's $57M enough to get pivotal data for lead cancer program
Double vision

Sofinnova Ventures led NuCana BioMed Ltd.'s $57 million B round in the hopes its founders can once again bring a nucleoside-based cancer therapy to market.

NuCana's ProTide technology adds a phosphoramidate moiety to oncologic nucleosides to improve their activity and safety. The company's Acelarin (NUC-1031) is a ProTide of gemcitabine that is in Phase I testing.

Co-founder and CEO Hugh Griffith said Acelarin overcomes gemcitabine's three primary resistance mechanisms. It enters cells independently of...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >